EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

PGC-1α drives small cell neuroendocrine cancer progression toward an ASCL1-expressing subtype with increased mitochondrial capacity

Grigor Varuzhanyan, Chia-Chun Chen, Jack Freeland, Tian He, Wendy Tran, Kai Song, Liang Wang, Donghui Cheng, Shili Xu iD, Gabriella A Dibernardo, Favour N Esedebe, Vipul Bhatia und 9 weitere

Proceedings of the National Academy of Sciences · 2024

DOI: 10.1073/pnas.2416882121 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2024. Verfasst von Grigor Varuzhanyan und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology Immunology and Molecular Genetics, University of California, Los Angeles, CA 90095. Hauptthemen laut MEDLINE: Basic Helix-Loop-Helix Proteins, Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha, Mitochondria, Oxidative Phosphorylation. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: G. Harold and Leila Y. Mathers Foundation (Mathers Foundation), BLRD VA, Veteran Affairs funds.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adenocarcinomas from multiple tissues can converge to treatment-resistant small cell neuroendocrine (SCN) cancers composed of ASCL1, POU2F3, NEUROD1, and YAP1 subtypes. We investigated how mitochondrial metabolism influences SCN cancer (SCNC) progression. Extensive bioinformatics analyses encompassing thousands of patient tumors and human cancer cell lines uncovered enhanced expression of proliferator-activatedreceptor gamma coactivator 1-alpha (PGC-1α), a potent regulator of mitochondrial oxidative phosphorylation (OXPHOS), across several SCNCs. PGC-1α correlated tightly with increased expression of the lineage marker Achaete-scute homolog 1, (ASCL1) through a positive feedback mechanism. Analyses using a human prostate tissue-based SCN transformation system showed that the ASCL1 subtype has heightened PGC-1α expression and OXPHOS activity. PGC-1α inhibition diminished OXPHOS, reduced SCNC cell proliferation, and blocked SCN prostate tumor formation. Conversely, PGC-1α overexpression enhanced OXPHOS, validated by small-animal Positron Emission Tomography mitochondrial imaging, tripled the SCN prostate tumor formation rate, and promoted commitment to the ASCL1 lineage. These results establish PGC-1α as a driver of SCNC progression and subtype determination, highlighting metabolic vulnerabilities in SCNCs across different tissues.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Basic Helix-Loop-Helix ProteinsPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaMitochondriaOxidative PhosphorylationDisease ProgressionHumansMaleAnimalsCell Line, TumorMiceProstatic NeoplasmsGene Expression Regulation, NeoplasticNeuroendocrine TumorsCell Proliferation

Stichwörter der Autor:innen

ASCL1PGC-1alung canceroxidative phosphorylationprostate cancer

Substanzen

Basic Helix-Loop-Helix ProteinsPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaPPARGC1A protein, humanASCL1 protein, human

Autor:innen und Institutionen

  • Department of Microbiology Immunology and Molecular Genetics, University of California, Los Angeles, CA 90095.
  • Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA 90095.
  • Molecular Biology Interdepartmental Program, University of California, Los Angeles, CA 90095.
  • Department of Bioengineering, University of California, Los Angeles, CA 90095.
  • Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, CA 90095.
  • Crump Institute for Molecular Imaging, David Geffen School of Medicine, University of California, Los Angeles, CA 90095.

ORCID-Profile: Shili Xu, Evan R Abt, Thomas G Graeber, Owen N Witte

Förderung

  • G. Harold and Leila Y. Mathers Foundation (Mathers Foundation)
  • BLRD VA
  • Veteran Affairs funds
  • UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research predoctoral fellowship
  • NIH (NIH)
  • NCI NIH HHS
  • NIH HHS
  • Parker Institute for Cancer Immunotherapy (PICI)

Zitieren

APA

Varuzhanyan, G., Chen, C. C., Freeland, J., He, T., Tran, W., Song, K., Wang, L., Cheng, D., Xu, S., Dibernardo, G. A., Esedebe, F. N., Bhatia, V., Han, M., Abt, E. R., Park, J. W., Memarzadeh, S., Shackelford, D. B., Lee, J. K., Graeber, T. G., …, & Witte, O. N. (2024). PGC-1α drives small cell neuroendocrine cancer progression toward an ASCL1-expressing subtype with increased mitochondrial capacity. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2416882121

Vancouver

Varuzhanyan G, Chen CC, Freeland J, He T, Tran W, Song K, et al. PGC-1α drives small cell neuroendocrine cancer progression toward an ASCL1-expressing subtype with increased mitochondrial capacity. Proceedings of the National Academy of Sciences. 2024. doi:10.1073/pnas.2416882121

BibTeX
@article{Varuzhanyan2024,
  author = {Varuzhanyan, Grigor and Chen, Chia-Chun and Freeland, Jack and He, Tian and Tran, Wendy and Song, Kai and Wang, Liang and Cheng, Donghui and Xu, Shili and Dibernardo, Gabriella A and Esedebe, Favour N and Bhatia, Vipul and Han, Mingqi and Abt, Evan R and Park, Jung Wook and Memarzadeh, Sanaz and Shackelford, David B and Lee, John K and Graeber, Thomas G and Shirihai, Orian S and Witte, Owen N},
  title = {PGC-1α drives small cell neuroendocrine cancer progression toward an ASCL1-expressing subtype with increased mitochondrial capacity},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2024},
  doi = {10.1073/pnas.2416882121}
}
Kostenlos starten →